BioCentury
ARTICLE | Clinical News

Regenerative Patch Technologies' CPCB-RPE1 successfully implanted in AMD patients

April 27, 2018 7:48 PM UTC

Top-line data from the Phase I portion of a Phase I/IIa trial showed that CPCB-RPE1 from Regenerative Patch Technologies Inc. (Glendale, Calif.) was successfully implanted into an eye of four of five patients with non-neovascular age-related macular degeneration (AMD). The candidate was not successfully implanted in one patient due to intra-operative fibrinoid debris in the subretinal space of the eye. Data were published in Science Translational Medicine.

CPCB-RPE1 is a polarized monolayer of human embryonic stem cell-derived retinal pigment epithelium on an ultrathin, synthetic parylene substrate designed to mimic Bruch’s membrane...